Prospective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndrome

Blood

Volumn 111, Issue 7, 2008, Pages 3802-3812

  Robinson, Blaine W ^a   Cheung, Nai Kong V ^b   Kolaris, Christos P ^a   Jhanwar, Suresh C ^b   Choi, John K ^c   Osheroff, Neil ^d   Felix, Carolyn A ^a,c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ASPARAGINASE; BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; DRUG METABOLITE; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ISOTRETINOIN; MELPHALAN; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3F8; ONCOPROTEIN; TACROLIMUS; THIOTEPA; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; HOMEODOMAIN PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; MLL PROTEIN, HUMAN; MYELOID ECOTROPIC VIRAL INTEGRATION SITE 1 PROTEIN; TUMOR PROTEIN;

ARTICLE; BLAST CELL; CASE REPORT; CELL FATE; CHILD; CHROMOSOME BREAKAGE; CHROMOSOME TRANSLOCATION; CLONE; CONTROLLED STUDY; DROSOPHILA MELANOGASTER; FUSION GENE; GENE EXPRESSION; GENE TARGETING; GENE TRANSLOCATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; MALE; MEIS1 GENE; MLL FRYL GENE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUROBLASTOMA; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; ANIMAL; AUTOTRANSPLANTATION; BIOSYNTHESIS; BONE MARROW; CHROMOSOME 12; CHROMOSOME 4; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SEQUENCE HOMOLOGY;

ALKYLATING AGENTS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 12; CHROMOSOMES, HUMAN, PAIR 4; COMBINED MODALITY THERAPY; DNA TOPOISOMERASES, TYPE II; DROSOPHILA MELANOGASTER; ETOPOSIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HOMEODOMAIN PROTEINS; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASM PROTEINS; NEUROBLASTOMA; ONCOGENE PROTEINS, FUSION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROSPECTIVE STUDIES; SEQUENCE HOMOLOGY, AMINO ACID; TRANSLOCATION, GENETIC; TRANSPLANTATION, AUTOLOGOUS;

EID: 43549112363     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-07-096065     Document Type: Article

References (81)

1. NakamuraT, Mori T, Tada S, et al. ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell. 2002;10:1119-1128.
2. YokoyamaA, Kitabayashi I, Ayton PM, Cleary ML, Ohki M. Leukemia proto-oncoprotein MLL is proteolytically processed into 2 fragments with opposite transcriptional properties. Blood. 2002;100:3710-3718.
3. Hsieh JJ, Cheng EH, Korsmeyer SJ. Taspasel: a threonine aspartase required for cleavage of MLL and proper HOX gene expression. Cell. 2003;115:293-303.
4. Meyer C, Schneider B, Jakob S, et al. The MLL recombinome of acute leukemias. Leukemia. 2006;20:777-784.
5. YokoyamaA. Wang Z. Wysocka J. et al. Leukemia proto-onco protein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol Cell Biol. 2004;24:5639-5649.
6. Kumar AR, Hudson WA, Chen W, Nishiuchi R. Yao Q, Kersey JH. Hoxa9 influences the phenotype but not the incidence of MII-AF9 fusion gene leukemia. Blood. 2004;103:1823-1828.
7. Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002;30:41-47.
8. Armstrong SA, KungAL, Mabon ME, et al. Inhibition of FLT 3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 2003;3:173-183.
9. Brown P, Levis M, Shurtleff S, Campana D, Downing J, Small D. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood. 2005;105:812-820.
10. Stam RW, den Boer ML, Schneider P, et al. Targeting FLT3 in primary MLL gene rearranged infant acute lymphoblastic leukemia. Blood. 2005;106:2484-2490.
11. Ayton PM, Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene. 2001 ;20:5695-5707.
12. Corral J, Lavenir I, Impey H, et al. An MII-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell. 1996; 85:853-861.
13. Lavau C, Szilvassy SJ, Slany R, Cleary ML. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. Embo J. 1997;16:4226-4237.
14. Lavau C, Du C, Thirman M, Zeleznik-Le N. Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. Embo J. 2000;19:4655-4664.
15. Lavau C, Luo RT, Du C, Thirman MJ. Retrovirusmediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice. Proc Natl Acad Sci USA. 2000;97:10984-10989.
16. So CW, Karsunky H, Passegue E. Cozzio A. Weissman IL Cleary ML. MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice. Cancer Cell. 2003;3:161-171.
17. Chen W, Li Q, Hudson WA, Kumar A, Kirchhof N, Kersey JH. A murine MII-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy. Blood. 2006;108:669-677.
18. Fuchs U, Rehkamp G, Haas OA, et al.The human formin-binding protein 17 (FBP17) interacts with sorting nexin, SNX2, and is an MLL-fusion partner in acute myelogeneous leukemia. Proc Natl Acad Sci USA. 2001 ;98:8756-8761.
19. Strehl S, Borkhardt A, Slany R, Fuchs UE, Konig M, Haas OA. The human LASP1 gene is fused to MLL in an acute myeloid leukemia with t(11;17)(q23;q21). Oncogene. 2003;22:157-160.
20. Taki T, Shibuya N, Taniwaki M, et al. ABI-1, a human homolog to mouse Abl-interactor 1, fuses the MLLgene in acute myeloid leukemia with t(10;11)(p11.2;q23). Blood. 1998;92:1125-1130.
21. Borkhardt A, Bojesen S, Haas OA, et al. The human GRAF gene is fused to MLL in a unique t(5; 11 )(q31 ;q23) and both alleles are disrupted in three cases of myelodysplastic syndrome/acute myeloid leukemia with a deletion 5q. Proc Natl Acad Sci USA. 2000;97:9168-9173.
22. Teuffel O, Betts DR, Thali M, et al. Clonal expansion of a new MLL rearrangement in the absence of leukemia. Blood. 2005;105:4151-4152.
23. Hayette S, Cornillet-Lefebvre P, Tigaud I, et al. AF4p12, a human homologue to the furry gene of Drosophila, as a novel MLLfusion partner. Cancer Res. 2005;65:6521-6525.
24. Rasio D, Schichman SA, Negrini M, Canaani E, Croce CM. Complete exon structure of the ALL1 gene. Cancer Res. 1996;56:1766-1769.
25. Nilson I, Lochner K, Siegler G, et al. Exon/intron structure of the human ALL-1 (MLL) gene involved in translocations to chromosomal region 11q23 and acute leukaemias. Br J Haematol. 1996;93:966-972.
26. Meyer C, Kowarz E, Schneider B. et al. Genomic DNA of leukemic patients: target for clinical diagnosis of MLL rearrangements. Biotechnol J. 2006;1:656-663.
27. GuY, NakamuraT,Alder H, et al.The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell. 1992;71:701-708.
28. Robinson BW, Slater DJ, Felix CA. Bglll-based panhandle and reverse panhandle PGR approaches increase capability for cloning der(ll) and der(other) genomic breakpoint junctions of MLL translocations. Genes Chromosomes Cancer. 2006;45:740-753.
29. Lovett BD, Strumberg D, Blair IA, et al. Etoposide metabolites enhance DNA to poisomerase II cleavage near leukemia-associated MLL translocation breakpoints. Biochemistry. 2001;40:1159-1170.
30. Whitmarsh RJ, Saginario C, Zhuo Y et al. Reciprocal DNA topoisomerase II cleavage events at 5′-TATTA-3′ sequences in MLL and AF-9 create homologous single-stranded overhangs that anneal to form der(11) and der(9) genomic breakpoint junctions in treatment-related AML without further processing. Oncogene. 2003;22:8448-8459.
31. Wassermann K, Markovits J, Jaxel C, Capranico G, Kohn KW, PommierY. Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II. Mol Pharmacol. 1990:38:38-45.
32. -ΔΔCT method. Methods. 2001 ;25: 402-408.
33. Hasle H, Niemeyer CM, Chessells JM, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 2003;17:277-282.
34. Megonigal MD, Cheung NK, Rappaport EE et al. Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors. Proc Natl Acad Sci USA. 2000;97:2814-2819.
35. Raffini LJ. Slater DJ, Rappaport EE et al. Panhandle and reverse-panhandle PCR enable cloning of der(11) and der(other) genomic breakpoint junctions of MLL translocations and identify complex translocation of MLL, AF-4, and CDK6. Proc Natl Acad Sci USA. 2002;99:4568-4573.
36. Gillert E, LeisT, Repp R. et al. A DNA damage repair mechanism is involved in the origin of chromosomal translocations t(4;11) in primary leukemic cells. Oncogene. 1999;18:4663-4671.
37. Jackson SP. Sensing and repairing DNA double-strand breaks. Carcinogenesis. 2002;23:687-696.
38. Weinstock DM, Richardson CA, Elliott B, Jasin M. Modeling oncogenic translocations: Distinct roles tor double-strand break repair pathways in translocation formation in mammalian cells. DNA Repair (Amst). 2006;5:1065-1074.
39. Cong J, Geng W, He B, Liu J, Charlton J, Adler PN. The furry gene of Drosophila is important for maintaining the integrity of cellular extensions during morphogenesis. Development. 2001;128: 2793-2802.
40. Felix GA, Kolaris CP, Osheroff N. Topoisomerase II and the etiology of chromosomal translocations. DNA Repair (Amst). 2006;5:1093-1108.
41. Capranico G, Binaschi M. DNA sequence selectivity of topoisomerases and topoisomerase poisons. Biochim Biophys Acta. 1998;1400:185-194.
42. Kanai M, Kume K. Miyahara K, et al. Fission yeast M025 protein is localized at SPB and septum and is essential for cell morphogenesis. Embo J. 2005;24:3012-3025.
43. Sano K, Hayakawa A, Piao JH, Kosaka Y, Nakamura H. Novel SH3 protein encoded by the AF3p21 gene is fused to the mixed lineage leukemia protein in a therapy-related leukemia with t(3;11) (p21 ;q23). Blood. 2000;95:1066-1068.
44. Pegram LD, Megonigal MD, Lange BJ, et al. t(3; 11) translocation in treatment-related acute myeloid leukemia fuses MLL with the GMPS (GUANOSINE 5' MONOPHOSPHATE SYNTHETASE) gene. Blood. 2000;96:4360-4362.
45. Rowley JD, Reshmi S, Sobulo O, et al. All patients with the T(11 ;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood. 1997;90:535-541.
46. Smith MA. Rubinstein L Ungerleider RS. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks. Med Pediatr Oncol. 1994;23:86-98.
47. Pedersen-Bjergaard J, Rowley JD. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood. 1994;83:2780-2786.
48. Zeisig BB, Milne T, Garcia-Cuellar MP, et al. Hoxa9 and Meisl are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol. 2004;24:617-628.
49. Taketani T, Taki T, Sugita K, et al. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood. 2004;103:1085-1088.
50. Libura M, Asnafi V, Tu A, et al. FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress. Blood. 2003;102: 2198-2204.
51. Wong P, Iwasaki M, Somervaille TC, So CW, Cleary ML. Meisl is an essential and rate-limiting regulator of MLL leukemia stem cell potential [published correction appears in Genes Dev. 2007;21:3017]. Genes Dev. 2007;21:2762-2774.
52. Johnson JJ, Chen W, Hudson W, et al. Prenatal and postnatal myeloid cells demonstrate stepwise progression in the pathogenesis of MLL fusion gene leukemia. Blood. 2003;101:3229-3235.
53. Blanco JG. Dervieux T, Edick MJ. et al. Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2001 ;98:10338-10343.
54. Domer PH, Head DR. Renganathan N, Raimondi SC, Yang E, Atlas M. Molecular analysis of 13 cases of MLL/11q23 secondary acute leukemia and identification of topoisomerase II consensus- binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4;11). Leukemia. 1995;9:1305-1312.
55. Lovett BD, Lo Nigro L, Rappaport EE et al. Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment- related acute lymphoblastic leukemia with t(4;11) translocation. Proc Natl Acad Sci USA. 2001 ;98: 9802-9807.
56. LangerT, Metzler M, Reinhardt D, et al. Analysis of t(9;11) chromosomal breakpoint sequences in childhood acute leukemia: almost identical MLL breakpoints in therapy-related AML after treatment without etoposides. Genes Chromosomes Cancer. 2003;36:393-401.
57. Atlas M, Head D, Behm F, et al. Cloning and sequence analysis of four t(9;11) therapy-related leukemia breakpoints. Leukemia. 1998;12:1895-1902.
58. Megonigal MD, Rappaport EE, Jones DH, et al. Panhandle PCR strategy to amplify MLL genomic breakpoints in treatment-related leukemias. Proc Natl Acad Sci USA. 1997;94:11583-11588.
59. Sobulo OM, Borrow J, Tomek R, et al. MLL is fused to CBP, a histone acetytransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc Natl Acad Sci USA. 1997;94:8732-8737.
60. Povirk LR. Biochemical mechanisms of chromosomal translocations resulting from DNA double- strand breaks. DNA Repair (Amst). 2006;5:1199-1212.
61. Betti CJ, Villalobos MJ, Diaz MO, Vaughan AT. Apoptotic triggers initiate translocations within the MLL gene involving the nonhomologous end joining repair system. Gancer Res. 2001 ;61:4550- 4555.
62. Sim SP, Liu LR. Nucleolytic cleavage of the mixed lineage leukemia breakpoint cluster region during apoptosis. J Biol Chem. 2001 ;276:31590-31595.
63. Betti CJ, Villalobos MJ, Diaz MO, Vaughan AT. Apoptotic stimuli initiate MLL-AR9 translocations that are transcribed in cells capable of division. Cancer Res. 2003;63:1377-1381.
64. Stanulla M, Wang J, Chervinsky DS,Thandla S, Apian PD. DNA cleavage within the MLL breakpoint cluster region is a specific event which occurs as part of higher-order chromatin fragmentation during the initial stages of apoptosis. Mol Gell Biol. 1997;17:4070-4079.
65. Ng A, Taylor GM, Wynn RR, Eden OB. Effects of topoisomerase 2 inhibitors on the MLL gene in children receiving chemotherapy: a prospective study. Leukemia. 2005;19:253-259.
66. Schichman SA, Caligiuri MA, Strout MP, et al. ALL-1 tandem duplication in acute myeloid leukemia with a normal karyotype involves homologous recombination between Alu elements. Cancer Res. 1994;54:4277-4280.
67. Gu Y, Cimino G, Alder H, et al. The (4; 11 )(q21: q23) chromosome translocations in acute leukemias involve the VDJ recombinase. Proc Natl Acad Sci USA. 1992:89:10464-10468.
68. Le Deley MC, Leblanc T, Shamsaldin A, et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol. 2003;21:1074-1081.
69. Pedersen-Bjergaard J, Andersen MK, Christiansen DH. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood. 2000;95:3273-3279.
70. Biethahn S, Alves F, Wilde S, Hiddemann W, Spiekermann K. Expression of granulocyte colony-stimulating factor- and granulocyte-macrophage colony-stimulating factor-associated signal transduction proteins of the JAK/STAT pathway in normal granulopoiesis and in blast cells of acute myelogenous leukemia. Exp Hematol. 1999;27:885-894.
71. Relling MV, Boyett JM, Blanco JG, et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood. 2003;101:3862-3867.
72. Hershman D, Neugut AL Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst. 2007;99:196-205.
73. Le Deley MC, Suzan F, Cutuli B, et al. Anthracyclines, mitoxantrone. radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol. 2007;25:292-300.
74. Rosenberg PS, Alter BP, BolyardAA, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood. 2006; 107:4628-4635.
75. Tigue CC, McKoy JM. Evens AM. Trifilio SM, Tall- man MS, Bennett CL. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant. 2007;40:185-192.
76. Berger R, Le Coniat M, Derre J, Vecchione D, Jonveaux P. Cytogenetic studies in acute promyelocytic leukemia: a survey of secondary chromosomal abnormalities. Genes Chromosomes Cancer. 1991;3:332-337.
77. Orion E, Matz H, Wolf R. The life-threatening complications of dermatologic therapies. Clin Dermatol. 2005;23:182-192.
78. Ratain MJ, Kaminer LS. Bitran JD, et al. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood. 1987;70:1412-1417.
79. Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipo-dophyllotoxins for acute lymphoblastic leukemia. N Engl J Med. 1991;325:1682-1687.
80. Felix CA, Hosier MR, Winick NJ, Masterson M, Wilson AE, Lange BJ. ALL-1 gene rearrangements in DNAtopoisomerase II inhibitor-related leukemia in children. Blood. 1995;85:3250-3256.
81. Winick NJ, McKenna RW, Shuster JJ, et al. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol. 1993:11:209-217.